美国健赞公司

出自 MBA智库百科(http://wiki.mbalib.com/)

(重定向自Genzyme Corp.)
健赞公司(Genzyme Corporation)
健赞公司(Genzyme Corporation)

美国健赞公司网站网址http://www.genzyme.com/

目录

美国健赞公司简介

  美国健赞公司(Genzyme Corporation, NASDAQ: GENZ)是全球较早成立的前十大生物制药公司,也是前二十大纳斯达克上市公司。其销售产值排全球前十位,是生物制药领域的五大企业之一。作为当今世界知名生物技术公司之一,健赞致力于研究和治疗患有严重疾病的病人。于1981年成立于波士顿,现已成长为年收入超过30亿美元,全球超过8000名员工的多样化企业。一直致力于发展和应用生命科学中最先进的技术以服务于医学的需要。它所生产产品和提供的医学服务救助着超过80个国家的患者,其产品主要集中于罕见遗传病、肾病、骨关节炎、免疫系统疾病和诊断测试。健赞公司至今仍在不断创新,继续研究开发基因遗传、免疫系统疾病、心脏病和癌症等病症。

  2011年,美国健赞公司为赛诺菲-安万特收购

Genzyme Corporation

  One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

  With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Overview of Genzyme Corporation

  Genzyme is one of the world’s leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.

  Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of $4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.

  Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Genzyme focuses on the following broad areas of medicine:

  • Genetics Diseases
  • Cardiometabolic and Renal
  • Oncology
  • Orthopaedics/Biosurgical Specialties
  • Transplant
  • Genetics/Diagnostics

  Research and Development

  Genzyme's research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. In 2008, Genzyme invested approximately $750 million in this work, or about 16 percent of its revenues.

  Genzyme continues to build its pipeline through both internal research and licensing and acquisitions, focusing on product candidates with the potential to change the standard of care for serious diseases. The company’s broad pipeline features seven major late-stage programs, including: alemtuzumab for multiple sclerosis; Clolar for adult acute myeloid leukemia; and mipomersen for familial hypercholesterolemia and other high risk, high cholesterol patients.

  Corporate Responsibility

  Corporate responsibility is a priority at Genzyme. The company’s commitment to patients extends beyond the development of new treatments and the services needed to deliver them. Genzyme has a strong presence in developing countries, where it provides free medicine to patients and helps to build sustainable health care systems. The company in 2006 launched an initiative to support the development of treatments for neglected diseases that affect hundred of millions of people in the developing world. Genzyme’s headquarters is one of the most environmentally responsible office buildings in the world, and the company is a leader in waste-reduction and recycling efforts.

  In addition, Genzyme supports science education and health initiatives in the communities in which it operates. For these and other efforts, Genzyme has been consistently included in the Dow Jones Sustainability World Index, which consists of companies that excel in economic, environmental and social performance. For the past three years, Genzyme was named one of the "Global 100 Most Sustainable Corporations in the World" by Innovest Strategic Value Advisors. BusinessWeek has ranked Genzyme as one of the top corporate givers, and the company has also been recognized by the U.S. Environmental Protection Agency, the American Association for the Advancement of Science, and many other organizations.

提示 本条目仅是MBA智库百科美国健赞公司的介绍。若您需要与美国健赞公司联系,请访问美国健赞公司官方网站。

本条目对我有帮助10

分享到:
  如果您认为本条目还有待完善,需要补充新内容或修改错误内容,请编辑条目

本条目由以下用户参与贡献

Cabbage,鲈鱼,方小莉,刘维燎.

评论(共1条)

提示:评论内容为网友针对条目"美国健赞公司"展开的讨论,与本站观点立场无关。
42.236.240.* 在 2017年2月11日 12:30 发表

已退市 信息更新维护是个大问题

回复评论

发表评论请文明上网,理性发言并遵守有关规定。

以上内容根据网友推荐自动排序生成